AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical
solutions for peripheral nerve injuries, today announced its
participation at the 71st Annual American Society for Surgery of
the Hand Meeting taking place in Austin, Texas from September 29 -
October 1, 2016.
AxoGen will sponsor several special programs
that support peripheral nerve education and awareness, including
the Hand Fellows pre-course program, the ‘Women in Hand Surgery’
event and a surgeon led symposium - ‘Tackling Challenges in Nerve
Repair: A Case-Based Discussion’. AxoGen’s full portfolio of nerve
repair and assessment products will be featured at ASSH Booth
#526.
In addition to our education and awareness
efforts, the most recent data from the RANGER® Registry, will be
presented in the scientific session. The presentation from
the RANGER Registry investigators will provide further insight into
the role of Avance® Nerve Graft in the reconstruction of upper
extremity nerve injuries.
“We are excited to see peripheral nerve repair
take such a prominent role in this year’s conference with 30
separate presentations,” stated Karen Zaderej, AxoGen’s President
and Chief Executive Officer. “Hand surgeons are often faced with
challenging nerve injuries and we are pleased to provide scientific
data and clinical discussions in support of the role of AxoGen’s
portfolio in nerve repair.”
AxoGen will also be hosting a Nerve Repair
Discussion Event for the investment community on Wednesday,
September 28, preceding the ASSH Meeting. The Event will include
the presentation of clinical data from clinical thought leaders and
a discussion of peripheral nerve repair focusing on surgeon
adoption, development of treatment algorithms, and the growing body
of clinical evidence.
Key AxoGen sponsored nerve related presentation
details for the ASSH Meeting are as follows:
Friday, September 30,
2016AxoGen Breakfast Symposium: Tackling
Challenges in Nerve Repair: A Case-Based DiscussionInvited
Faculty: Gregory M. Buncke, MD, Fraser Leversedge, MD, Peter J.
Evans, MD, PhD
RANGER® Registry Data
PresentationCan Processed Nerve Allografts be used
to Repair Nerve Injuries Greater than 4 cm for the Return of
Critical Function in the Upper ExtremityAuthors: Bauback
Safa, MD, Jozef Zoldos, MD, Timothy Niacaris, MD, PhD, Leon Nesti,
MD, PhD, Jason Ko, MD, Gregory M. Buncke, MD
Details for the AxoGen Nerve Repair Discussion
Event for the investment community preceding the ASSH Meeting are
as follows:
Wednesday, September 28,
2016AxoGen Nerve Repair Discussion
EventLocation: Getaway Motor Club; 3700
Thompson St., Austin, Texas 78702Time: 3:30pm to
6:30pm CDTParticipating surgeons: Ivica Ducic, MD PhD, Bauback
Safa, MD FACS, Peter Evans, MD PhD FRCSCNote that this event is an
interactive discussion of nerve repair and will not be webcast.
Investors who are interested in attending the event can register by
email to AxoGenEvents@troutgroup.com.
About the RANGER® StudyThe
RANGER® Study, A Multicenter Retrospective Study of Avance® Nerve
Graft Utilization Evaluations and Outcomes in Peripheral Nerve
Injury Repair is an active, multicenter clinical database with 18
contributing centers designed to continuously monitor and collect
injury, repair, safety and outcomes data for peripheral nerve
injuries repaired with processed nerve allograft (Avance® Nerve
Graft), nerve autograft and synthetic tubes. As of July 2016, the
study included more than 900 nerve repairs enrolled across 18
centers and 48 surgeons. The RANGER® Study is an AxoGen sponsored
ongoing open label registry study. Each patient outcome is
dependent upon the nature and extent of nerve loss or damage,
timing between nerve loss and repair and the natural course of the
patient’s recovery. Results presented at the ASSH meeting may not
represent typical clinical outcomes for individual patients.
About ASSH 2016The American
Society for Surgery of the Hand is the oldest and most prestigious
medical society dedicated to the hand and upper extremity. Its
mission is to advance the science and practice of hand and upper
extremity surgery through education, research and advocacy on
behalf of patients and practitioners. For more information, please
visit https://www.assh.org/.
About AxoGen AxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen’s portfolio of products includes Avance® Nerve
Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix ("ECM") coaptation aid for
tensionless repair of severed nerves, and AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
injured peripheral nerves and reinforce the nerve reconstruction
while minimizing soft tissue attachments. Along with these core
surgical products, AxoGen also offers AxoTouch™ Two-Point
Discriminator and AcroVal™ Neurosensory & Motor Testing System.
These evaluation and measurement tools assist healthcare
professionals in detecting changes in sensation, assessing return
of sensory, grip and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom and several European and
international countries.
Cautionary Statements Concerning Forward-Looking
StatementsThis Press Release contains "forward-looking" statements
as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made, and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2024 to May 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From May 2023 to May 2024